The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 13 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Oak HC/FT rejects cold-calling sourcing models used by TA and Insight
“We don't cold call. We're not like a TA or an insight, have a bank of kids that are, they're trying to find deals. Just not the way it works.”
Lamont: Multi-stage venture firms have an advantage over standalone seed funds
“And even I think seed funds are having trouble because firms that can do seed startup series A, B, C, and promise to be there with the entrepreneur all the way along, have an advantage against an even a early stage seed fund.”
Mega-funds cannot maintain senior partner involvement across every portfolio company
“You get as many people and as much money as they have, there's no way the senior people are involved with every company, and we are, and that will remain.”
Oak HC/FT invested in Paxos at $2B and quickly saw 2x offers
“We just invested in a company, Paxos, a couple months ago, two billion dollar valuation. We're already getting offers at more than twice that for that company.”
Oak HC/FT never hires external consultants like McKinsey for due diligence
“And then otherwise, we don't hire McKinsey. We don't hire Bain. We never hire a consultant.”
Lamont: Oak Investment Partners agreed to wind down and dissolve
“But the existing entity, Oak Investment Partners, wasn't going to exist any longer. That entity, we all agreed, was going to die. We were going to roll off all the companies, and we were the surviving new entity, essentially, Oak HCFT, so you could call us Oak…”
Oak HC/FT refuses to invest directly in FDA-risk biotech
“In terms of directly investing into biotech and life sciences companies that take FDA risk, we won't do that.”
Oak HC/FT companies accounted for 30% of $100M+ sector rounds in 2021
“I mean, we were, last year, we were, 30% of the rounds that were done, over a hundred million in our sectors, were OKCFT companies. And that is a pretty powerful stat, and those were all over a billion dollar rounds, in terms of valuation.”
Lamont: Oak HC/FT invests in digital asset infrastructure, not crypto tokens
“On the crypto side, we haven't been investing in it As a currency. We haven't been investing in crypto per se, but we invest in digital asset infrastructure. So Paxos is digital asset infrastructure.”
Lamont: One-third of Oak HC/FT deals sit at the healthcare-fintech intersection
“Fintech and payments is really embedded in every industry, and it's one of the reasons there was incredible conversions between healthcare and fintech, two highly regulated industries, but a third of what we do is the overlap between these two sectors.”
Lamont: Female VC and CEO Representation Will Rise Concurrently
“You're going to see more female CEOs at the same time you're seeing more VCs, and it's happening.”